In­dus­try, FDA be­gin to ham­mer out PDU­FA VII de­tails

Dis­cus­sions con­tin­ue be­tween in­dus­try and the FDA re­gard­ing the up­com­ing reau­tho­riza­tion of user fees for pre­scrip­tion drugs, bi­o­log­ics and gener­ic drugs. Af­ter pub­lic hear­ing and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER